Ascendis Pharma (NASDAQ:ASND) – Wedbush dropped their Q3 2018 earnings per share (EPS) estimates for shares of Ascendis Pharma in a note issued to investors on Thursday, April 5th, according to Zacks Investment Research. Wedbush analyst L. Moussatos now expects that the biotechnology company will post earnings per share of ($0.98) for the quarter, down from their prior forecast of ($0.97). Wedbush currently has a “Outperform” rating and a $67.00 target price on the stock. Wedbush also issued estimates for Ascendis Pharma’s FY2018 earnings at ($3.89) EPS, FY2019 earnings at ($4.81) EPS, FY2020 earnings at ($5.47) EPS, FY2021 earnings at ($2.91) EPS and FY2022 earnings at $1.87 EPS.
Several other equities research analysts have also recently commented on ASND. ValuEngine upgraded Ascendis Pharma from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Leerink Swann restated a “market perform” rating and set a $64.00 price target (up previously from $37.00) on shares of Ascendis Pharma in a research note on Monday, April 2nd. JPMorgan Chase upped their price objective on Ascendis Pharma to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, March 21st. Credit Suisse Group upped their price objective on Ascendis Pharma from $50.00 to $78.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. Finally, BidaskClub raised Ascendis Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $65.83.
Ascendis Pharma stock opened at $62.13 on Monday. Ascendis Pharma has a 12 month low of $21.95 and a 12 month high of $69.00.
A number of hedge funds have recently made changes to their positions in ASND. JPMorgan Chase & Co. acquired a new position in Ascendis Pharma during the third quarter worth $7,163,000. Citadel Advisors LLC acquired a new stake in Ascendis Pharma in the third quarter valued at $372,000. Wells Fargo & Company MN grew its holdings in Ascendis Pharma by 788.8% in the third quarter. Wells Fargo & Company MN now owns 30,076 shares of the biotechnology company’s stock valued at $1,090,000 after purchasing an additional 26,692 shares during the last quarter. Allianz Asset Management GmbH acquired a new stake in Ascendis Pharma in the third quarter valued at $4,366,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Ascendis Pharma in the third quarter valued at $3,988,000. 73.48% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Wedbush Analysts Cut Earnings Estimates for Ascendis Pharma (NASDAQ:ASND)” was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://macondaily.com/2018/04/16/q3-2018-eps-estimates-for-ascendis-pharma-asnd-decreased-by-wedbush-updated.html.
Ascendis Pharma Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
Get a free copy of the Zacks research report on Ascendis Pharma (ASND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.